https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
Lung cancer is the leading cause of cancer death in the world. Natural product deguelin and its truncated analogs have been reported to be potential therapeutic agents for lung cancer. In order to improve the potency, a novel truncated deguelin derivative (4) possessing nitric oxide (NO) donor was designed and synthesized. The biological evaluation showed that hybrid 4 exerted potent activity with an IC50 value of 0.41 μM in H1299 cells. Mechanism studies showed that it arrested the cell cycle at G2/M phase and suppressed Hs
Like
Comment
Share
